Rafarma pharmaceutical updates
December 18, 2024 09:00 ET
|
Rafarma Pharmaceuticals Inc.
Sheridan, Wyoming, USA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) Dear Rafarma shareholders, We apologize for the delay in providing information about the company's...
EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management
October 30, 2024 07:26 ET
|
European Academy of Allergy and Clinical Immunology
The European Academy of Allergy and Clinical Immunology (EAACI) has released updated "Clinical Guidelines on the Management of IgE-mediated Food Allergy."
Rafarma Pharmaceutical news update
November 30, 2023 09:30 ET
|
Rafarma Pharmaceuticals Inc.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet...
Developing New Treatments for Mania Using Brain-Based Risk Markers - A Free Webinar from the Brain & Behavior Research Foundation
November 04, 2021 08:59 ET
|
Brain & Behavior Research Foundation
New York, Nov. 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing New Treatments for Mania Using Brain-Based Risk Markers” on...
IMAC Holdings Announces Closing of its Public Offering of Common Stock for Total Gross Proceeds of $17.0 Million
March 26, 2021 11:18 ET
|
IMAC Holdings, Inc.
Brentwood, Tenn., March 26, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (the “Company” or “IMAC”) (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in...